<DOC>
	<DOCNO>NCT02779465</DOCNO>
	<brief_summary>The purpose study determine whether vitamin D effective prevention hepatocellular carcinoma patient chronic hepatitis B .</brief_summary>
	<brief_title>Oral Vitamin D Treatment Prevention Hepatocellular Carcinoma</brief_title>
	<detailed_description>Potential participant identify follow-up cohort chronic hepatitis B third Affiliated Hospital Sun Yat-sen University ( 3rd SYSU ) . The hepatologists 3rd SYSU 's Infectious Disease Institute ask potential participant she/he interested participating . If patient express interest study , one researcher meet patient he/she 3rd SYSU regular appointment describe study potential participant . If patient continue interested participating , she/he give copy review board approve consent document read . The consent document use guide explain study detail patient . The participant allocate experimental group contact one investigator research team instruct begin take 2 tablet per day ( 800 IU total ) vitamin D3 besides regular anti-virus treatment . Those patient allocate control group inform take vitamin D3 follow control study . The researcher investigate general treatment benefit potential reduce development Hepatocellular carcinoma ( HCC ) , also know liver cancer . Improvement treatment benefit determine interview patient , level HBsAg HBeAg , development liver fibrosis evidence HCC routine imaging .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>All subject age 18 70 chronic hepatitis B oral antivirus treatment follow Third Affiliated Hospital Sun Yatsen University , Guangzhou , China , offer entry study . The diagnosis chronic Hepatitis B base positive hepatitis B surface antigen ( HBsAg ) least six month , positive HBeAg negative HBeAg detectable HBV DNA screen . No evidence HCC entry image study . Model End Stage Liver Disease ( MELD ) score 22 ( MELD score 22 would predict 3 month mortality rate approximately 20 % ) . Not currently participate another intervention study . Not pregnant lactating , willing use effective contraception study period . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Ability provide write informed consent accord national/local regulation . evidence hepatocellular carcinoma within 6 month enrollment , serum alanine aminotransferase level 10 time upper limit normal , elevate serum creatinine level , diagnosis kidney stone , diagnosis hyperparathyroidism serious disturbance calcium metabolism past 5 year , evidence autoimmune hepatitis , coinfection hepatitis C D virus human immunodeficiency virus , serious concurrent illness ( e.g. , alcoholism , uncontrolled diabetes , cancer ) , treatment immunomodulatory within 6 month screen , treatment investigational drug within 30 day study begin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>vitamin D treatment</keyword>
	<keyword>chronic hepatitis B</keyword>
</DOC>